الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 104 |  |  |
| | | from | 104 | | |
Abstract
Malignant T cells are known tb have alterations in multiple cellular signaling pathways, wi;1ich open new avenues for targeted therapy. However, these I therapeutic agents are largely in the preclinical stage. Because of the complexities in the communication between multiple signaling networks, in. addition to the combination of specific inhibitors that target only one pathway, multi-targeted agents, including the natural products, should be considered to further improve the therapeutic efficiency of T -cell malignancies. [ Mayer -1997] Anti-CD52-based therapy of T eel/lymphoma) I Peripheral T-cell lymphoma uJspecified (PTCLIU) is a rare tumor characterized by poor tre’4tment response and a dismal prognosis. Furthermore, CD52 gene expression was studied in 28 cases for which RNA was ava~lable. We found that CD52 is expressed in approximately 40% of PTCLslU at the same level as in normal T-lymphocytes. Alt~ough other factors may playa role in the in vivo response tol alemtuzumab, an anti-CD52 monoclonal antibody, the estimation of CD52 expression may provide a rationale for the selection of patients with a higher . probability of treatment response. [Salomon et aI., -1997] Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of tumors that the WHO classification basically subdivides into specified and unspecified (D). In Western countries, they correspond to 15% of non-Hodgkin’s lymphomas, and more often present in advanced stage in middle aged/elderly patients who die I rapidly despite aggressive therapies. Recently, novel clinica~pathological scores have been proposed to improve prognostic stratification of PTCLIU patients. However, novel targeted therapies are needed.